CEBPA and acute myeloid leukemia: Patients diagnosed with AML with biallelic CEBPA gene mutations have a longer overall survival and event-free survival compared to those with a monoallelic CEBPA mutation or CEBPA-wild-type, therefore justifying the recognition of this group as a distinct provisional entity.